Interference of levamisole with inhibition of E-rosette formation by Hodgkin's disease and systemic lupus erythematosus cytotoxic sera. 1979

G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni

A new system has been used to test the influence of levamisole on T-cell function. Evidence has been produced that prior exposure to the drug "protects" normal human peripheral blood lymphocytes from the inhibition that cytotoxic sera from patients with Hodgkin's disease and systemic lupus erythematosus exhibit on their E-rosette-forming capacity. Also, damage of this T-cell function already induced by Hodgkin's sera may be partially corrected.

UI MeSH Term Description Entries
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012397 Rosette Formation The in vitro formation of clusters consisting of a cell (usually a lymphocyte) surrounded by antigenic cells or antigen-bearing particles (usually erythrocytes, which may or may not be coated with antibody or antibody and complement). The rosette-forming cell may be an antibody-forming cell, a memory cell, a T-cell, a cell bearing surface cytophilic antibodies, or a monocyte possessing Fc receptors. Rosette formation can be used to identify specific populations of these cells. Immunocytoadherence,Formation, Rosette,Formations, Rosette,Immunocytoadherences,Rosette Formations

Related Publications

G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
October 1975, Annals of the rheumatic diseases,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
December 1980, Arthritis and rheumatism,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
January 1983, Acta medica Hungarica,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
March 1976, Ryumachi. [Rheumatism],
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
January 1983, International archives of allergy and applied immunology,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
June 1994, International journal of dermatology,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
April 1991, Human pathology,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
January 1976, Terapevticheskii arkhiv,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
January 1977, Arthritis and rheumatism,
G S Del Giacco, and S Tognella, and A L Leone, and F Locci, and P Cornaglia, and A Sangiuolo, and V Grifoni
September 1979, Annals of allergy,
Copied contents to your clipboard!